立方制药(003020) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥333,618,253.50, a decrease of 58.90% compared to ¥811,816,818.00 in the same period last year[3] - Net profit attributable to shareholders was ¥30,372,220.01, down 54.08% from ¥66,141,680.02 year-on-year[3] - The basic earnings per share decreased by 53.66% to ¥0.19 from ¥0.41 in the previous year[3] - Total operating revenue for Q1 2024 was CNY 333,618,253.50, a decrease of 58.9% compared to CNY 811,816,818.00 in the same period last year[24] - Net profit for Q1 2024 was CNY 27,455,521.45, a decline of 58.5% from CNY 66,141,680.02 in the previous year[25] - Earnings per share for Q1 2024 were CNY 0.19, compared to CNY 0.41 in Q1 2023[25] Cash Flow - The company reported a net cash flow from operating activities of ¥15,482,874.04, a decline of 28.32% compared to ¥21,600,909.33 in the same period last year[3] - Total cash inflow from operating activities was ¥381,665,137.63, down 40% from ¥634,636,626.42 year-on-year[27] - Cash outflow from operating activities totaled ¥366,182,263.59, a reduction of 40.4% compared to ¥613,035,717.09 in the previous year[27] - The net cash flow from investing activities was -¥328,421,286.75, an improvement from -¥401,062,190.31 in Q1 2023[28] - Cash inflow from investing activities was ¥1,459,925.70, compared to -¥1,358.92 in the same period last year[28] - Cash outflow from investing activities was ¥329,881,212.45, down 17.6% from ¥401,060,831.39 year-on-year[28] - The net cash flow from financing activities was -¥2,435,065.43, a significant decrease from ¥39,276,135.89 in Q1 2023[28] - The ending balance of cash and cash equivalents was ¥187,350,348.71, down from ¥237,039,230.28 at the end of the previous year[28] - The company’s cash and cash equivalents decreased by ¥315,371,864.11 compared to a decrease of ¥340,189,083.67 in the same period last year[28] Assets and Liabilities - The total assets at the end of Q1 2024 were ¥2,494,372,525.00, a slight increase of 0.43% from ¥2,483,679,575.17 at the end of the previous year[3] - The company's total liabilities decreased to CNY 585,545,562.34 from CNY 610,181,560.50 at the beginning of the period, a reduction of 4.0%[22] - Total equity increased to CNY 1,908,826,962.66 from CNY 1,873,498,014.67, reflecting a growth of 1.9%[22] - The company's cash and cash equivalents decreased to RMB 187,746,356.52 from RMB 502,928,970.18 at the beginning of the period[19] - Accounts receivable increased to RMB 282,187,801.20 from RMB 258,447,324.51 at the beginning of the period[20] - Inventory decreased to RMB 231,136,836.50 from RMB 242,914,365.17 at the beginning of the period[20] - The company’s long-term equity investments increased to RMB 169,598,898.44 from RMB 163,951,200.01 at the beginning of the period[20] Research and Development - Research and development expenses increased by 87.78% to ¥2,354,680.00, reflecting the company's commitment to advancing its R&D projects[10] - Research and development expenses for Q1 2024 were CNY 23,546,764.47, an increase of 88.0% compared to CNY 12,539,427.60 in the same period last year[24] - The company plans to continue focusing on R&D and market expansion despite the recent financial challenges[10] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,085, indicating a stable shareholder base[12] - The company completed the repurchase and cancellation of 31,964 restricted stocks, accounting for 0.02% of the total share capital before repurchase[15] Regulatory and Certification - The company received the drug registration certificate for Itraconazole Oral Solution during the reporting period[14] - The registration applications for Lidocaine Hydrochloride and Danpi Phenol raw materials were accepted, and the registration for Mesalazine Enteric-Coated Tablets was also accepted[14] - The company was awarded the High-tech Enterprise Certificate, valid for three years, on November 30, 2023[16] Management Changes - The company appointed a new representative for continuous supervision due to the previous representative's work adjustment[17] Investment Income - The company reported a decrease in investment income by 1038.80% to ¥343,320.00, primarily due to increased contributions from Huaren Lifang[10] - The company reported an investment income of CNY 3,433,225.39, compared to a loss of CNY 365,672.63 in the previous year[25] Trading Financial Assets - The company experienced a significant increase in trading financial assets by 424.21% to ¥32,249,240.00 due to cash purchases of structured deposits[7]